Shanghai RAAS Blood Products Co Ltd
SZSE:002252

Watchlist Manager
Shanghai RAAS Blood Products Co Ltd Logo
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Watchlist
Price: 7.45 CNY -3.37% Market Closed
Market Cap: 98.5B CNY
Have any thoughts about
Shanghai RAAS Blood Products Co Ltd?
Write Note

Relative Value

The Relative Value of one Shanghai RAAS Blood Products Co Ltd stock under the Base Case scenario is 7.26 CNY. Compared to the current market price of 7.45 CNY, Shanghai RAAS Blood Products Co Ltd is Overvalued by 3%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
7.26 CNY
Overvaluation 3%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
76
vs Industry
56
Median 3Y
12.6
Median 5Y
14.4
Industry
7.7
Forward
11.3
vs History
47
vs Industry
6
Median 3Y
52.1
Median 5Y
57.2
Industry
22.7
Forward
39.6
vs History
9
vs Industry
6
Median 3Y
50.5
Median 5Y
68.5
Industry
21.6
vs History
3
vs Industry
5
Median 3Y
62.2
Median 5Y
81.9
Industry
25.2
vs History
52
vs Industry
47
Median 3Y
3.1
Median 5Y
3.4
Industry
2.5
vs History
74
vs Industry
50
Median 3Y
12.2
Median 5Y
13.8
Industry
7.7
Forward
10.9
vs History
57
vs Industry
29
Median 3Y
28.6
Median 5Y
31.5
Industry
9
vs History
79
vs Industry
6
Median 3Y
43.6
Median 5Y
52.9
Industry
4.2
Forward
31.8
vs History
79
vs Industry
6
Median 3Y
43.6
Median 5Y
52.9
Industry
4.1
Forward
33.3
vs History
11
vs Industry
7
Median 3Y
48.1
Median 5Y
66.5
Industry
5.7
vs History
3
vs Industry
5
Median 3Y
59.4
Median 5Y
79
Industry
3.6
vs History
53
vs Industry
48
Median 3Y
3.4
Median 5Y
3.6
Industry
4.6

Multiples Across Competitors

Competitors Multiples
Shanghai RAAS Blood Products Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
98.5B CNY 11.8 55.3 40.9 40.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
CN
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Average P/E: 182.8
55.3
68%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Average EV/EBITDA: 20.6
40.9
54%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
CN
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Average EV/EBIT: 25.1
40.9
47%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top